BANCA MEDIOLANUM SPA (BMED.MI) Stock Fundamental Analysis
BIT:BMED - Euronext Milan - IT0004776628 - Common Stock - Currency: EUR
BMED gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Financial Services industry. While BMED is still in line with the averages on profitability rating, there are concerns on its financial health. BMED is not valued too expensively and it also shows a decent growth rate. Finally BMED also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BMED had positive earnings in the past year.
In the past year BMED had a positive cash flow from operations.
BMED had positive earnings in each of the past 5 years.
In multiple years BMED reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of 1.82%, BMED perfoms like the industry average, outperforming 42.00% of the companies in the same industry.
BMED has a better Return On Equity (38.86%) than 90.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.82% | ||
| ROE | 38.86% | ||
| ROIC | N/A |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BMED has a Profit Margin of 16.26%. This is in the better half of the industry: BMED outperforms 62.00% of its industry peers.
BMED's Profit Margin has improved in the last couple of years.
BMED does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.26% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
BMED has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BMED has more shares outstanding
Compared to 1 year ago, BMED has an improved debt to assets ratio.
2.2 Solvency
BMED has a debt to FCF ratio of 6.56. This is a slightly negative value and a sign of low solvency as BMED would need 6.56 years to pay back of all of its debts.
BMED has a Debt to FCF ratio (6.56) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.79 is on the high side and indicates that BMED has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.79, BMED is doing worse than 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.79 | ||
| Debt/FCF | 6.56 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC7.69%
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.00% over the past year.
The Earnings Per Share has been growing by 14.21% on average over the past years. This is quite good.
Looking at the last year, BMED shows a very strong growth in Revenue. The Revenue has grown by 44.99%.
Measured over the past years, BMED shows a small growth in Revenue. The Revenue has been growing by 0.11% on average per year.
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%81.82%
Revenue 1Y (TTM)44.99%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%11.52%
3.2 Future
The Earnings Per Share is expected to decrease by -4.80% on average over the next years.
Based on estimates for the next years, BMED will show a small growth in Revenue. The Revenue will grow by 1.26% on average per year.
EPS Next Y-19.14%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
EPS Next 5YN/A
Revenue Next Year-4.82%
Revenue Next 2Y1.08%
Revenue Next 3Y1.26%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.05 indicates a reasonable valuation of BMED.
Compared to the rest of the industry, the Price/Earnings ratio of BMED indicates a somewhat cheap valuation: BMED is cheaper than 72.00% of the companies listed in the same industry.
BMED is valuated cheaply when we compare the Price/Earnings ratio to 27.69, which is the current average of the S&P500 Index.
BMED is valuated correctly with a Price/Forward Earnings ratio of 12.46.
Based on the Price/Forward Earnings ratio, BMED is valued a bit cheaper than the industry average as 64.00% of the companies are valued more expensively.
BMED is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.36, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.05 | ||
| Fwd PE | 12.46 |
4.2 Price Multiples
76.00% of the companies in the same industry are more expensive than BMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.26 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as BMED's earnings are expected to decrease with -4.80% in the coming years.
PEG (NY)N/A
PEG (5Y)0.71
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 6.76%, BMED is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.62, BMED pays a better dividend. On top of this BMED pays more dividend than 94.00% of the companies listed in the same industry.
BMED's Dividend Yield is rather good when compared to the S&P500 average which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.76% |
5.2 History
On average, the dividend of BMED grows each year by 14.04%, which is quite nice.
Dividend Growth(5Y)14.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
37.38% of the earnings are spent on dividend by BMED. This is a low number and sustainable payout ratio.
DP37.38%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
BIT:BMED (7/24/2025, 3:24:53 PM)
15.075
+0.06 (+0.43%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)
Earnings (Next)
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners40.28%
Ins Owner ChangeN/A
Market Cap11.24B
Analysts82.5
Price Target15.93 (5.67%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.76% |
Yearly Dividend0.79
Dividend Growth(5Y)14.04%
DP37.38%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.19%
Min EPS beat(2)1.77%
Max EPS beat(2)42.6%
EPS beat(4)3
Avg EPS beat(4)10.87%
Min EPS beat(4)-1.3%
Max EPS beat(4)42.6%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-32.79%
Min Revenue beat(2)-44.68%
Max Revenue beat(2)-20.91%
Revenue beat(4)0
Avg Revenue beat(4)-25.64%
Min Revenue beat(4)-44.68%
Max Revenue beat(4)-12.99%
Revenue beat(8)0
Avg Revenue beat(8)-20.01%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.06%
PT rev (3m)3.86%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.05 | ||
| Fwd PE | 12.46 | ||
| P/S | 1.17 | ||
| P/FCF | 10.26 | ||
| P/OCF | 9.75 | ||
| P/B | 2.79 | ||
| P/tB | 2.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.5
EY9.95%
EPS(NY)1.21
Fwd EY8.02%
FCF(TTM)1.47
FCFY9.75%
OCF(TTM)1.55
OCFY10.25%
SpS12.91
BVpS5.4
TBVpS5.12
PEG (NY)N/A
PEG (5Y)0.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.82% | ||
| ROE | 38.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.26% | ||
| GM | N/A | ||
| FCFM | 11.39% |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.79 | ||
| Debt/FCF | 6.56 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 95.34% | ||
| Cap/Sales | 0.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 70.03% | ||
| Current Ratio | N/A | ||
| Quick Ratio | N/A | ||
| Altman-Z | N/A |
F-Score7
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)87.43%
Cap/Depr(5y)95.87%
Cap/Sales(3y)2.01%
Cap/Sales(5y)1.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%81.82%
EPS Next Y-19.14%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
EPS Next 5YN/A
Revenue 1Y (TTM)44.99%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%11.52%
Revenue Next Year-4.82%
Revenue Next 2Y1.08%
Revenue Next 3Y1.26%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y160.66%
FCF growth 3Y8.9%
FCF growth 5Y27.28%
OCF growth 1Y165.69%
OCF growth 3Y8.21%
OCF growth 5Y25.97%